Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group.

MLA

Pellicelli, A. M., et al. “Impact of Different Sofosbuvir-Based Direct Acting Antiviral (DAA) Regimen in Elderly Cirrhotic Patients: A Real World Experience from CLEO Group.” Digestive & Liver Disease, vol. 48, Feb. 2016, p. e42. EBSCOhost, https://doi.org/10.1016/j.dld.2015.12.099.

APA

Pellicelli, A. M., Pace Palitti, V., Vignally, P., Moretti, A., Tarquini, P., Scifo, G., Messina, V., Ascione, A., Izzi, A., D, A. C., Villani, R., Fondacaro, L., Fontanella, L., Guarascio, P., Alessio, L., Miglioresi, L., D, amico, E., Ettorre, G. M., Marignani, M., & Begini, P. (2016). Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group. Digestive & Liver Disease, 48, e42. https://doi.org/10.1016/j.dld.2015.12.099

Chicago

Pellicelli, A.M., V. Pace Palitti, P. Vignally, A. Moretti, P. Tarquini, G. Scifo, V. Messina, et al. 2016. “Impact of Different Sofosbuvir-Based Direct Acting Antiviral (DAA) Regimen in Elderly Cirrhotic Patients: A Real World Experience from CLEO Group.” Digestive & Liver Disease 48 (February): e42. doi:10.1016/j.dld.2015.12.099.